PMID- 34236497 OWN - NLM STAT- MEDLINE DCOM- 20210820 LR - 20210820 IS - 1432-0584 (Electronic) IS - 0939-5555 (Linking) VI - 100 IP - 9 DP - 2021 Sep TI - Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. PG - 2303-2310 LID - 10.1007/s00277-021-04560-6 [doi] AB - Chimeric antigen receptor (CAR) T-cell therapy provides long-term remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Total metabolic tumor volume (TMTV) assessed by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) has a confirmed prognostic value in the setting of chemoimmunotherapy, but its predictive role with CAR T-cell therapy is not fully established. Thirty-five patients with R/R LBCL who received CAR T-cells were included in the study. TMTV and maximum standardized uptake value (SUVmax) were measured at baseline and 1-month after CAR T-cell infusion. Best response included 9 (26%) patients in complete metabolic response (CMR) and 16 (46%) in partial metabolic response (PMR). At a median follow-up of 7.6 months, median PFS and OS were 3.4 and 8.2 months, respectively. A high baseline TMTV (>/= 25 cm(3)) was associated with a lower PFS (median PFS, 2.3 vs. 8.9 months; HR = 3.44 [95% CI 1.18-10.1], p = 0.02). High baseline TMTV also showed a trend towards shorter OS (HR = 6.3 [95% CI 0.83-47.9], p = 0.08). Baseline SUVmax did not have a significant impact on efficacy endpoints. TMTV and SUVmax values showed no association with adverse events. Metabolic tumor burden parameters measured by 18FDG-PET before CAR T-cell infusion can identify LBCL patients who benefit most from this therapy. CI - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Iacoboni, Gloria AU - Iacoboni G AUID- ORCID: 0000-0003-0805-9288 AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. giacoboni@vhio.net. AD - Department of Medicine, Universitat Autonoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. giacoboni@vhio.net. FAU - Simo, Marc AU - Simo M AD - Department of Medicine, Universitat Autonoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. AD - Department of Nuclear Medicine, Vall D'Hebron University Hospital, Barcelona, Spain. FAU - Villacampa, Guillermo AU - Villacampa G AD - Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. AD - SOLTI Breast Cancer Research Group, Barcelona, Spain. FAU - Catala, Eva AU - Catala E AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. FAU - Carpio, Cecilia AU - Carpio C AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. FAU - Diaz-Lagares, Candido AU - Diaz-Lagares C AD - Department of Intensive Care, Shock, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron University Hospital, Vall D Hebron Research Institute (VHIR), Barcelona, Spain. FAU - Vidal-Jordana, Angela AU - Vidal-Jordana A AD - Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain. FAU - Bobillo, Sabela AU - Bobillo S AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. FAU - Marin-Niebla, Ana AU - Marin-Niebla A AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. FAU - Perez, Ana AU - Perez A AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. FAU - Jimenez, Moraima AU - Jimenez M AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. FAU - Abrisqueta, Pau AU - Abrisqueta P AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. FAU - Bosch, Francesc AU - Bosch F AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. FAU - Barba, Pere AU - Barba P AD - Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. LA - eng PT - Journal Article DEP - 20210708 PL - Germany TA - Ann Hematol JT - Annals of hematology JID - 9107334 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Aged MH - Female MH - Fluorodeoxyglucose F18/analysis MH - Humans MH - *Immunotherapy, Adoptive MH - Lymphoma, Large B-Cell, Diffuse/*diagnosis/diagnostic imaging/metabolism/*therapy MH - Male MH - Middle Aged MH - Positron-Emission Tomography MH - Prognosis MH - Retrospective Studies MH - Tumor Burden OTO - NOTNLM OT - CAR T-cells OT - Maximum standardized uptake value OT - Positron emission tomography OT - Total metabolic tumor volume EDAT- 2021/07/09 06:00 MHDA- 2021/08/21 06:00 CRDT- 2021/07/08 12:24 PHST- 2020/12/18 00:00 [received] PHST- 2021/05/18 00:00 [accepted] PHST- 2021/07/09 06:00 [pubmed] PHST- 2021/08/21 06:00 [medline] PHST- 2021/07/08 12:24 [entrez] AID - 10.1007/s00277-021-04560-6 [pii] AID - 10.1007/s00277-021-04560-6 [doi] PST - ppublish SO - Ann Hematol. 2021 Sep;100(9):2303-2310. doi: 10.1007/s00277-021-04560-6. Epub 2021 Jul 8.